3/20
08:05 am
fdmt
4D Molecular Therapeutics (FDMT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $36.00 price target on the stock.
Medium
Report
4D Molecular Therapeutics (FDMT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $36.00 price target on the stock.
3/19
10:02 am
fdmt
Rating for FDMT
Low
Report
Rating for FDMT
3/19
10:02 am
fdmt
Rating for FDMT
Low
Report
Rating for FDMT
3/19
09:49 am
fdmt
4D Molecular Therapeutics (FDMT) had its "buy" rating reaffirmed by Chardan Capital. They now have a $26.00 price target on the stock.
Medium
Report
4D Molecular Therapeutics (FDMT) had its "buy" rating reaffirmed by Chardan Capital. They now have a $26.00 price target on the stock.
3/19
09:15 am
fdmt
Rating for FDMT
Low
Report
Rating for FDMT
1/28
08:35 am
fdmt
Rating for FDMT
High
Report
Rating for FDMT
1/28
08:35 am
fdmt
Rating for FDMT
High
Report
Rating for FDMT
1/28
08:03 am
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $33.00 price target on the stock.
Low
Report
4D Molecular Therapeutics (NASDAQ:FDMT) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $33.00 price target on the stock.
1/7
03:02 pm
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
1/7
03:02 pm
fdmt
4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Low
Report
4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.